RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/a-2166-6824
Diabetes and Fatty Liver
The DDG clinical practice guidelines are updated regularly during the second half of the calendar year. Please ensure that you read and cite the respective current version.
Change 1: For the screening of non-alcoholic fatty liver disease, reference was made to the updated S2k guideline on non-alcoholic fatty liver disease of the German Society for Gastroenterology, Digestive and Metabolic Diseases/Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) [7], the European algorithm of the EASL Clinical Practice Guidelines [8], and a recently proposed procedure for general practitioners and diabetologists [9]
Reason: New recommendation for structured screening for non-alcoholic fatty liver disease for general practitioners and diabetologists
Supporting reference: [7] [8] [9] [10]
Change 2: New results from pharmacological phase 2 therapy studies are given.
Reason: This provided important new insights into the possible future pharmacological therapy of non-alcoholic fatty liver disease.
Publikationsverlauf
Artikel online veröffentlicht:
07. Februar 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1
Younossi ZM.
Non-alcoholic fatty liver disease – A global public health
perspective. J Hepatol 2019; 70: 531-544
MissingFormLabel
- 2 Eigentler T, Lomberg D, Machann J. et al. Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade. Ann Intern Med 2020; 172: 836-837
- 3
Estes C,
Anstee QM,
Arias-Loste MT.
et al.
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain,
United Kingdom, and United States for the period 2016-2030. J Hepatol 2018; 69: 896-904
MissingFormLabel
- 4 Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 2019; 7: 313-324
- 5 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
- 6 Younossi ZM, Koenig AB, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
- 7 Roeb E, Canbay A, Bantel H. et al. Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021-025. Z Gastroenterol 2022; 60: 1346-1421
- 8 European Association for the Study of the Liver (EASL); European European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016; 59: 1121-1140
- 9 European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 2021; 75: 659-689
- 10 Younossi ZM, Corey KE, Alkhouri N. et al. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther 2020; 52: 513-526
- 11 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017; 14: 32-42
- 12 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357
- 13 Bril F, McPhaul MJ, Caulfield MP. et al. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 2019; 67: 303-311
- 14 Eslam M, Sanyal AJ, George J. et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158: 1999-2014.e1
- 15 Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature 2019; 576: 51-60
- 16 Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 2022; 10: 284-296
- 17 Rinella ME, Lazarus JV, Ratziu V et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78: 1966-1986
- 18 Singh S, Allen AM, Wang Z. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-654.e1-9
- 19 Adams LA, Anstee QM, Tilg H. et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-1153
- 20 Aminian A, Al-Kurd A, Wilson R. et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA 2021; 326: 2031-2042
- 21
Newsome PN,
Buchholtz K,
Cusi K.
et al.
A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic
steatohepatitis. N Engl J Med 2021; 384: 1113-1124
MissingFormLabel
- 22 Loomba R, Abdelmalek MF, Armstrong MJ. et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 2023; 8: 511-522
- 23 Francque SM, Bedossa P, Ratziu V. et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med 2021; 385: 1547-1558
- 24 Harrison SA, Bashir MR, Guy CD. et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2019; 394: 2012-2024
- 25 Loomba R, Sanyal AJ, Kowdley KV. et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med 2023; 389: 998-1008